Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
Adagio Medical treated the first patient with its next-generation vCLAS Ultra system under FDA Expanded Access, successfully addressing a complex ventricular tachycardia case that had failed previous treatments. The next-gen system features a single-freeze design at -170°C, with pre-clinical data indicating a potential 50-75% reduction in ablation time and procedures up to 30 minutes shorter.
Key figures
- Phase Of Trial
- Pivotal IDE
- Freedom from icd shock
- 84%
- Amiodarone use reduction
- 78%
- Major adverse events rate
- 2.4%
- Fulcrum vt patients enrolled
- 209
- Ablation time reduction potential
- 50-75%
- Procedure time reduction potential
- up to 30 minutes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.